These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35062017)

  • 1. SARS-CoV-2 transmissibility compared between variants of concern and vaccination status.
    Wang L; Didelot X; Bi Y; Gao GF
    Brief Bioinform; 2022 Mar; 23(2):. PubMed ID: 35062017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants.
    Chakraborty C; Sharma AR; Bhattacharya M; Agoramoorthy G; Lee SS
    mBio; 2021 Aug; 12(4):e0114021. PubMed ID: 34465019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
    Bui NN; Lin YT; Huang SH; Lin CW
    Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.
    Chung HY; Jian MJ; Chang CK; Lin JC; Yeh KM; Chen CW; Hsieh SS; Hung KS; Tang SH; Perng CL; Chang FY; Wang CH; Shang HS
    Microbiol Spectr; 2022 Feb; 10(1):e0251321. PubMed ID: 35196812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
    Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
    Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replication Kinetics of B.1.351 and B.1.1.7 SARS-CoV-2 Variants of Concern Including Assessment of a B.1.1.7 Mutant Carrying a Defective ORF7a Gene.
    Pyke AT; Nair N; van den Hurk AF; Burtonclay P; Nguyen S; Barcelon J; Kistler C; Schlebusch S; McMahon J; Moore F
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34200386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of an outbreak of symptomatic SARS-CoV-2 VOC 202012/01-lineage B.1.1.7 infection in healthcare workers, Italy.
    Loconsole D; Sallustio A; Accogli M; Leaci A; Sanguedolce A; Parisi A; Chironna M
    Clin Microbiol Infect; 2021 Aug; 27(8):1174.e1-1174.e4. PubMed ID: 33984489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence.
    Tatsi EB; Filippatos F; Michos A
    Epidemiol Infect; 2021 Nov; 149():e237. PubMed ID: 34732275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England.
    Volz E; Mishra S; Chand M; Barrett JC; Johnson R; Geidelberg L; Hinsley WR; Laydon DJ; Dabrera G; O'Toole Á; Amato R; Ragonnet-Cronin M; Harrison I; Jackson B; Ariani CV; Boyd O; Loman NJ; McCrone JT; Gonçalves S; Jorgensen D; Myers R; Hill V; Jackson DK; Gaythorpe K; Groves N; Sillitoe J; Kwiatkowski DP; ; Flaxman S; Ratmann O; Bhatt S; Hopkins S; Gandy A; Rambaut A; Ferguson NM
    Nature; 2021 May; 593(7858):266-269. PubMed ID: 33767447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico.
    Galán-Huerta KA; Flores-Treviño S; Salas-Treviño D; Bocanegra-Ibarias P; Rivas-Estilla AM; Pérez-Alba E; Lozano-Sepúlveda SA; Arellanos-Soto D; Camacho-Ortiz A
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing an Amplification Refractory Mutation System-Quantitative Reverse Transcription-PCR Assay for Rapid and Sensitive Screening of SARS-CoV-2 Variants of Concern.
    Xiong D; Zhang X; Shi M; Wang N; He P; Dong Z; Zhong J; Luo J; Wang Y; Yu J; Wei H
    Microbiol Spectr; 2022 Feb; 10(1):e0143821. PubMed ID: 34985323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid evolution of the COVID-19 pandemic calls for a unified public health response.
    He N
    Biosci Trends; 2021 Sep; 15(4):196-200. PubMed ID: 34193749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Epidemiological Traits by Analysis of SARS-CoV-2 Sequences.
    Pan B; Ji Z; Sakkiah S; Guo W; Liu J; Patterson TA; Hong H
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33925388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.
    Saxena SK; Kumar S; Ansari S; Paweska JT; Maurya VK; Tripathi AK; Abdel-Moneim AS
    J Med Virol; 2022 Apr; 94(4):1738-1744. PubMed ID: 34905235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 lineage B.6 was the major contributor to early pandemic transmission in Malaysia.
    Chong YM; Sam IC; Chong J; Kahar Bador M; Ponnampalavanar S; Syed Omar SF; Kamarulzaman A; Munusamy V; Wong CK; Jamaluddin FH; Chan YF
    PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008744. PubMed ID: 33253226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Pre-Vaccination Baseline of SARS-CoV-2 Genetic Surveillance and Diversity in the United States.
    Capoferri AA; Shao W; Spindler J; Coffin JM; Rausch JW; Kearney MF
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence and spread of the potential variant of interest (VOI) B.1.1.519 of SARS-CoV-2 predominantly present in Mexico.
    Rodríguez-Maldonado AP; Vázquez-Pérez JA; Cedro-Tanda A; Taboada B; Boukadida C; Wong-Arámbula C; Nuñez-García TE; Cruz-Ortiz N; Barrera-Badillo G; Hernández-Rivas L; López-Martínez I; Mendoza-Vargas A; Reyes-Grajeda JP; Alcaraz N; Peñaloza-Figueroa F; Gonzalez-Barrera D; Rangel-DeLeon D; Herrera-Montalvo LA; Mejía-Nepomuceno F; Hernández-Terán A; Mújica-Sánchez M; Becerril-Vargas E; Martínez-Orozco JA; Pérez-Padilla R; Salas-Hernández J; Sanchez-Flores A; Isa P; Matías-Florentino M; Ávila-Ríos S; Muñoz-Medina JE; Grajales-Muñiz C; Salas-Lais AG; Santos Coy-Arechavaleta A; Hidalgo-Miranda A; Arias CF; Ramírez-González JE
    Arch Virol; 2021 Nov; 166(11):3173-3177. PubMed ID: 34448936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Variants of Concern.
    Choi JY; Smith DM
    Yonsei Med J; 2021 Nov; 62(11):961-968. PubMed ID: 34672129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil.
    Goes LR; Siqueira JD; Garrido MM; Alves BM; Pereira ACPM; Cicala C; Arthos J; Viola JPB; Soares MA;
    Infect Genet Evol; 2021 Oct; 94():104998. PubMed ID: 34252616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.